BioNTech SE (BVMF:B1NT34)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of BRL 113.22 billion. The enterprise value is 29.61 billion.

Market Cap	113.22B
Enterprise Value	29.61B

Important Dates

The last earnings date was Tuesday, March 10, 2026.

Earnings Date	Mar 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.54%
Shares Change (QoQ)	+2.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.10
PB Ratio	0.91
P/TBV Ratio	1.01
P/FCF Ratio	62.32
P/OCF Ratio	38.39
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.03
EV / Sales	1.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	16.30

Financial Position

The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.01.

Current Ratio	7.54
Quick Ratio	6.87
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	0.95
Interest Coverage	-89.20

Financial Efficiency

Return on equity (ROE) is -5.88% and return on invested capital (ROIC) is -25.47%.

Return on Equity (ROE)	-5.88%
Return on Assets (ROA)	-3.56%
Return on Invested Capital (ROIC)	-25.47%
Return on Capital Employed (ROCE)	-6.38%
Weighted Average Cost of Capital (WACC)	12.56%
Revenue Per Employee	2.38M
Profits Per Employee	-941,108
Employee Count	7,807
Asset Turnover	0.13
Inventory Turnover	3.10

Taxes

In the past 12 months, BioNTech SE has paid 551.64 million in taxes.

Income Tax	551.64M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.99% in the last 52 weeks. The beta is 1.53, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.53
52-Week Price Change	-17.99%
50-Day Moving Average	34.39
200-Day Moving Average	35.26
Relative Strength Index (RSI)	35.06
Average Volume (20 Days)	1,374

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.69

Income Statement

In the last 12 months, BioNTech SE had revenue of BRL 18.56 billion and -7.35 billion in losses. Loss per share was -30.40.

Revenue	18.56B
Gross Profit	14.61B
Operating Income	-8.19B
Pretax Income	-6.80B
Net Income	-7.35B
EBITDA	-7.27B
EBIT	-8.19B
Loss Per Share	-30.40

Balance Sheet

The company has 88.86 billion in cash and 1.73 billion in debt, with a net cash position of 87.13 billion.

Cash & Cash Equivalents	88.86B
Total Debt	1.73B
Net Cash	87.13B
Net Cash Per Share	n/a
Equity (Book Value)	124.32B
Book Value Per Share	494.67
Working Capital	90.57B

Cash Flow

In the last 12 months, operating cash flow was 2.95 billion and capital expenditures -1.13 billion, giving a free cash flow of 1.82 billion.

Operating Cash Flow	2.95B
Capital Expenditures	-1.13B
Depreciation & Amortization	876.75M
Net Borrowing	-312.95M
Free Cash Flow	1.82B
FCF Per Share	n/a

Margins

Gross margin is 78.70%, with operating and profit margins of -44.14% and -39.59%.

Gross Margin	78.70%
Operating Margin	-44.14%
Pretax Margin	-36.61%
Profit Margin	-39.59%
EBITDA Margin	-39.17%
EBIT Margin	-44.14%
FCF Margin	9.79%

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.54%
Shareholder Yield	-0.54%
Earnings Yield	-6.49%
FCF Yield	1.60%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 21, 2022. It was a forward split with a ratio of 2.

Last Split Date	Nov 21, 2022
Split Type	Forward
Split Ratio	2

Scores

BioNTech SE has an Altman Z-Score of 6.72 and a Piotroski F-Score of 4.

Altman Z-Score	6.72
Piotroski F-Score	4